Revolution Medicines (RVMD) Stock Buyback History
TTM buyback yield N/A.
TTM buyback yield
N/A
Shareholder yield (TTM)
N/A
5Y share count change
185.5%
TTM buyback spend
N/A
SBC coverage (TTM)
0.00x
YoY change in spend
N/A
5Y CAGR of spend
N/A
Peak year (2018)
$131.00K
Cumulative spend
$176.00K
TTM metrics calculated from the four most recent reported quarters, ending .
Key takeaways
- Diluted share count is up 185.5% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $0.00 | $118.39M | −$118.39M | 0.19B | 13.3% | — |
| 2024 | $0.00 | $79.20M | −$79.20M | 0.17B | 48.2% | — |
| 2023 | $0.00 | $61.77M | −$61.77M | 0.11B | 40.3% | — |
| 2022 | $0.00 | $31.20M | −$31.20M | 0.08B | 10.7% | — |
| 2021 | $0.00 | $20.72M | −$20.72M | 0.07B | 9.3% | — |
| 2020 | $0.00 | $8.89M | −$8.89M | 0.07B | 82.6% | — |
| 2019 | $45.00K | $3.16M | −$3.12M | 0.04B | 0.0% | 0.00% |
| 2018 | $131.00K | $855.00K | −$724.00K | 0.04B | 0.0% | 0.01% |
| 2017 | $0.00 | $141.00K | −$141.00K | 0.04B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for Revolution Medicines (RVMD) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for Revolution Medicines (RVMD)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for Revolution Medicines (RVMD)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $0 | — | $0 | ||
| 2024 | $0 | — | $0 | ||
| 2023 | $0 | — | $0 | ||
| 2022 | $0 | — | $0 | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | -100.0% | -$45,000 | ||
| 2019 | $45,000 | -65.6% | -$86,000 | ||
| 2018 | $131,000 | — | +$131,000 | ||
| 2017 | $0 | — | — |
Revolution Medicines (RVMD) most recent annual buyback spend stands at $0 (2025).
Between 2018 and 2025, Revolution Medicines buyback spend plunged 100.0%, falling from $131,000 to $0.
Across the available history, buyback spend reached its high of $131,000 in 2018 and its low of $0 in 2017.
Among 8 Healthcare peers, Revolution Medicines (RVMD) ranks 8th; the peer median for buyback spend is $2.75B.
Revolution Medicines Buyback Spend 2025: $0
Revolution Medicines buyback spend in 2025 was $0.
Revolution Medicines Buyback Spend 2024: $0
Revolution Medicines buyback spend in 2024 was $0.
Revolution Medicines Buyback Spend 2023: $0
Revolution Medicines buyback spend in 2023 was $0.
Revolution Medicines Buyback Spend 2022: $0
Revolution Medicines buyback spend in 2022 was $0.
Revolution Medicines Buyback Spend 2021: $0
Revolution Medicines buyback spend in 2021 was $0.
See more financial history for Revolution Medicines (RVMD).
Sector peers by buyback spend
Companies in the same sector as Revolution Medicines, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Capital allocation mix
How Revolution Medicines splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from Revolution Medicines's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does Revolution Medicines buy back its own stock?
Yes, Revolution Medicines (RVMD) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
Is Revolution Medicines diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has Revolution Medicines's share count changed?
Diluted weighted average shares changed by about 185.5% over roughly five fiscal years (annual income statement data).
What is Revolution Medicines's buyback spend?
Latest reported buyback spend for Revolution Medicines (RVMD) is $0 (period ending March 31, 2026).
When did Revolution Medicines buyback spend hit its highest annual value?
Revolution Medicines buyback spend reached its highest annual value of $131,000 in 2018.
What was Revolution Medicines buyback spend in 2024?
Revolution Medicines (RVMD) buyback spend in 2024 was $0.
What was Revolution Medicines buyback spend in 2025?
Revolution Medicines (RVMD) buyback spend in 2025 was $0.
Explore more
RVMD Overview
Company profile, financial tools, and key metrics
RVMD What If Invested
What if you had invested $1,000? See historical returns from any date.
RVMD How It Makes Money
Discover visual breakdown — where revenue comes from and where it goes.
RVMD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
RVMD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
RVMD Daily Price Character
Explosive · 50.7% historical win rate (green days). Streaks & record days.
RVMD Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.